New obesity drug shows promise in keeping weight off after switching from popular GLP-1 meds
NCT ID NCT07575399
First seen May 14, 2026 · Last updated May 18, 2026 · Updated 1 time
Summary
This study tests whether switching from common weight-loss drugs (GLP-1 receptor agonists) to a new medication called maridebart cafraglutide helps adults with obesity or overweight maintain weight loss. About 300 participants who have already lost at least 10% of their body weight on a GLP-1 drug will be switched to the new drug for 68 weeks. The goal is to see if the new drug is safe, tolerable, and effective at keeping weight off.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY OR OVERWEIGHT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.